Evaluation of Efficacy and Safety of AGP on Immune Enhancement
NCT ID: NCT03330392
Last Updated: 2017-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2017-07-01
2017-10-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AGP
take two tablets per day (500 mg/day) for 8 weeks.
AGP
take two tablets per day (500 mg/day) for 8 weeks
Placebo
take two tablets per day for 8 weeks.
Placebo
take two tablets per day (500 mg/day) for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AGP
take two tablets per day (500 mg/day) for 8 weeks
Placebo
take two tablets per day (500 mg/day) for 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* have had at least two cold in the last 12 months.
Exclusion Criteria
* subjects taking medications such as immune related drug or functional foods
* history of disease that could interfere with the test products or impede their absorption
* pregnant or lactating women and heavy smokers.
* being judged by the responsible physician of the local study center as unfit to participate in the study
20 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chonbuk National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Soo-Wan Chae
Principal Investigator, Clinical Trial Center for Functional Foods
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Center for Functional Foods Chonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTCF2_2017_AGP
Identifier Type: -
Identifier Source: org_study_id